Thirty-Seventh Board Meeting

Loading...
Date
YYYY-MM-DD
Board Meeting Decision Point Number Title
2017-05-03 B37 GF/B37/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Ambassador Deborah Birx from the United States constituency is designated as Rapporteur for the 37th Board Meeting.</p>
2017-05-03 B37 GF/B37/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 37th Board Meeting (GF/B37/01- Revision 4) is approved.</p>
2017-05-03 B37 GF/B37/DP03 Board Chair and Vice-Chair Terms of Reference Board Chair and Vice-Chair Terms of Reference
<ol> <li>The Board approves the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B37/22- Revision 1 (the “Terms of Reference”), which shall enter into force upon the conclusion of the 37th Board Meeting in May 2017.</li> <li>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</li> </ol>
2017-05-03 B37 GF/B37/DP04: Appointment of the Board Chair and Vice-Chair Appointment of the Board Chair and Vice-Chair
<p>The Board appoints Aida Kurtović as Chair of the Board and Ambassador John Simon as ViceChair of the Board to each serve two-year terms, or until the appointment of their respective successors, starting from the adjournment of the 37th Board Meeting.</p>
2017-05-03 B37 GF/B37/DP05 2016 Annual Financial Report 2016 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Annual Financial Report, which includes the 2016 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B37/02 Annex 1.</p>
2017-05-03 B37 GF/B37/DP06 2016 Statutory Financial Statements 2016 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B37/02 Annex 2.</p>
2017-05-03 B37 GF/B37/DP07 Administration Agreement with the World Bank Administration Agreement with the World Bank
<ol> <li>The Board: <ol type="a"> <li>Notes the proposed Administration Agreement between the World Bank and the Global Fund for the Performance Based Funding project in the Democratic Republic of Congo, as presented in GF/B37/03- Revision 1 (the “Administration Agreement”);</li> <li>Acknowledges the Administration Agreement does not provide the Global Fund the right of access to books, records, personnel or sites relating to the Performance Based Funding project, including as required under the Board-approved Charter of the Office of the Inspector General; and</li> <li>Acknowledges that, accordingly, the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, on the funds disbursed under the Administration Agreement.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board authorizes the Secretariat to enter into the Administration Agreement with the World Bank for the Performance Based Funding project in the Democratic Republic of Congo in accordance with the financial and programmatic terms presented in GF/B37/03-Revision 1.</li> <li>However, the Board confirms that this decision does not set a precedent for future investments with development partners or for existing relationships with partners and requests the Secretariat develop a framework to guide future consideration of such investments for presentation to and review by the Audit and Finance Committee, in consultation with the Strategy Committee, for recommendation to the Board.</li> </ol>
2017-05-03 B37 GF/B37/DP08 Approval of Revisions to the Amended and Restated Global Fund Policy for Restricted Financial Contributions Approval of Revisions to the Amended and Restated Global Fund Policy for Restricted Financial Contributions
<ol> <li>Based on the recommendations of the Audit and Finance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as revised and set forth in Annex 1 to GF/B37/04 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy as approved by the Board in November 2014 under decision point GF/B32/DP13.</li> </ol>
2017-05-04 B37 GF/B37/DP09 Wambo.org: Progress Update and Steps for Advancement Wambo.org: Progress Update and Steps for Advancement
<ol> <li>The Board acknowledges the progress update on wambo.org presented by the Secretariat and notes the proposal contained in the paper “Wambo.org: Progress Update and Steps for Advancement”, as set forth in GF/B37/07 – Revision 2, to pilot a limited number of transactions by current Principal Recipients (“PRs”) using domestic funding via wambo.org.</li> <li>Based on the recommendation of the Strategy Committee, the Board approves the piloting of a limited number of transactions (at a maximum ten in total) by current PRs using domestic funding via wambo.org.</li> <li>Accordingly, the Board: <ol type="i"> <li>requests that the Secretariat: (i) provide to the Strategy Committee, by its next meeting, clearly defined draft indicators of success for the pilot; and (ii) report regularly to the Strategy Committee on the operationalization of this pilot, including any lessons learned from such transactions in light of the long-term perspective for wambo.org; and</li> <li>delegates to the Strategy Committee the authority to approve further transactions with domestic funding through wambo.org on a pilot basis, with the objective to provide input into further strategic and operational planning for wambo.org.</li> </ol> </li> </ol>
2017-05-04 B37 GF/B37/DP10 Appointment of the 2017 Executive Director Nomination Committee Membership Appointment of the 2017 Executive Director Nomination Committee Membership
<ol> <li>The Board acknowledges the nomination of members for the 2017 Executive Director Nomination Committee (the “Nomination Committee”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as members of the Nomination Committee as described below, in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B36/EDP11 and set out in Annex 1 to GF/B36/ER10: <ol type="a"> <li>Michèle Boccoz, Chair of the Nomination Committee;</li> <li>Vinand Nantulya, Vice- Chair of the Nomination Committee;</li> <li>Ala Alwan, Member;</li> <li>Sarah Boulton, Member, EGC Member;</li> <li>Joanne Carter, Member;</li> <li>Julie Essiam, Member;</li> <li>William Steiger, Member;</li> <li>Peter Felix, Independent Member</li> <li>Reinhard Tittel-Gronefeld, Independent Member</li> </ol> </li> <li>The Board requests the Nomination Committee to start the 2017 recruitment process for the next Executive Director.</li> </ol>
2017-05-04 B37 GF/B37/DP11 Health Situation in Venezuela Health Situation in Venezuela
<ol> <li>The Board expresses: <ol type="a"> <li>Continued concern about the resurgence of malaria, shortages of critical commodities for HIV and TB, and broader health crisis in Venezuela and its impact on the region; and</li> <li>Appreciation for the engagement of communities, civil society groups, PAHO, UNAIDS, WHO and others and their efforts to raise awareness and explore solutions for this situation.</li> </ol> </li> <li>The Board discussed the situation at length, noting Venezuela is currently not eligible for Global Fund financing, and calls for a coordinated regional response to the health crisis in Venezuela and that addresses the impact on the region incorporating relevant partners, donors and financers.</li> <li>Under such circumstances, in the context of a regional response, the Global Fund will continue to engage and, if possible, support the regional response</li> <li>The Board directs the Strategy Committee and the Secretariat to discuss exceptional circumstances in non-eligible countries as part of the ongoing review of the Eligibility Policy.</li> </ol>
2017-05-04 B37 GF/B37/DP12 Amended and Restated Global Fund Quality Assurance Policy for Diagnostic Products Amended and Restated Global Fund Quality Assurance Policy for Diagnostic Products
<p>Based on the recommendation of the Strategy Committee, the Board approves the amended and restated Global Fund Quality Assurance Policy for Diagnostic Products, as set forth in Annex 1 to GF/B37/06.</p>
2017-05-04 B37 GF/B37/DP13 Recognition of Dr. Mark Dybul Recognition of Dr. Mark Dybul
<p>At the end of his term, the Board wishes to sincerely thank Mark Dybul for the exceptional leadership, vision, and passion he displayed throughout his tenure as Executive Director.</p> <p>Through his tireless, humble, far-sighted efforts to expand and maximize the impact of the Global Fund partnership, Dr. Dybul has inspired all partners to go farther than many thought possible: two successful Replenishments; implementation of a new funding model; shifting operations and attitudes to embrace a strong focus on impact; strengthening partnerships to deliver our mission; supporting the Board in devising a new Strategy; and developing forward-looking initiatives to better promote sustainability and innovation.</p> <p>The Board additionally recognizes Dr. Dybul’s role in enhancing the relationship between the Board and the Secretariat. Through strengthening this relationship, he has helped the Global Fund remain targeted on achieving its mission and focused on best serving those affected by the three diseases.</p> <p>The Board wishes Dr. Dybul every success in the future.</p>
2017-05-04 B37 GF/B37/DP14 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Mr. Norbert Hauser for his leadership as Chair of the Board. Over his time working with the Global Fund, he has shown a high degree of personal commitment, willingness to devote his time and energy, and passion for the work of the Global Fund. During his tenure, Norbert has presided over significant and complex deliberations and decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Aida Kurtović for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and continues to show her personal conviction for the mission of the Global Fund by focusing her efforts as the incoming Chair of the Board. During her tenure as Vice-Chair, Aida has been an active driver of relationship building and collaborations that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board delivered the enhanced governance structure, strengthened ties across Global Fund stakeholders, and helped to guide and direct external relations.</p> <p>The Board wishes Norbert every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Aida into her new role, and looks forward to her tenure, as Chair of the Board.</p>
2017-08-14 B37 GF/B37/EDP01 Approval of the Report of the 37th Board Meeting in Kigali, Rwanda Approval of the Report of the 37th Board Meeting in Kigali, Rwanda
<p>Approval of the Report of the 37th Board Meeting in Kigali, Rwanda </p>
2017-09-08 B37 GF/B37/EDP02 Decision on the Secretariat’s Recommendation on Reinvestment of Funding from the 2014-2016 Allocation to Burkina Faso Across Country Disease Components Decision on the Secretariat’s Recommendation on Reinvestment of Funding from the 2014-2016 Allocation to Burkina Faso Across Country Disease Components
<p>The Board:</p> <ol> <li>Approves the reinvestment of funds from the TB-HIV grant BFA-C-IPC and the RSSH grant BFA-S-PADS to the malaria grant BFA-M-PADS, as listed in Table 1 of Section IV to GF/B36/ER01 (“Table 1”);</li> <li>Affirms the reinvestment of funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of the grant BFA-M-PADS, (b) decreases the upper-ceiling amount that may be available for the relevant implementation period(s) of the TB/HIV grant BFA-C-IPC and RSSH grant BFA-S-PADS, (c) is subject to the availability of funding, and (d) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-09-18 B37 GF/B37/EDP03 Appointment of Members to the Audit and Finance Committee and the Strategy Committee Appointment of Members to the Audit and Finance Committee and the Strategy Committee
<p>The Board:</p> <ol> <li>Approves the appointment of Madame Perrine Bonvalet-Doring, representing the French Constituency, as a voting member of the Audit and Finance Committee (“AFC”);</li> <li>Ambassador Anders Nordström, representing the Point Seven Constituency, as a voting member of the Strategy Committee (“SC”); and</li> <li>Doctor Manabu Sumi, representing the Japan Constituency, as a voting member of the SC,</li> </ol> <p>Each for a term that will expire in May 2018, or until the appointment of their successors</p>
2017-10-06 B37 GF/B37/EDP04 Selection of the Global Fund Executive Director: Contingency Voting Procedures Selection of the Global Fund Executive Director: Contingency Voting Procedures
<p>Decision Point GF/B37/EDP04: Approval of Contingency Voting Procedures</p> <ol> <li>The Board recalls: <ol type="a"> <li>its approval at the 36th Board Meeting of the voting procedure for the selection of the Executive Director, as set forth as part of the Summary of Voting Process in Annex 2 to GF/B36/07 (the “Summary of Voting Process”); and</li> <li>the contingency procedures in the event of ties/deadlock, described in section 3 of the Summary of Voting Process, to be proposed for Board approval in advance of any voting.</li> </ol> </li> <li>As contemplated in the Summary of Voting Process, the Board approves the following contingency procedures: <ol type="a"> <li>In the event of a tie during weighted voting cycles: <ol type="i"> <li>the more-preferred candidate will be allowed to proceed (i.e., the candidate with the higher number of first and second place points will move forward);</li> <li>if the tie persists after applying paragraph 2.a.i of this decision point, the Board shall repeat the voting cycle; and</li> <li>except in the cycle with the final two candidates, if the tie continues to persist, both candidates will be removed from consideration.</li> </ol> </li> <li>In the event of deadlock in the final affirmative vote (i.e., if the final candidate is not selected with an affirmative two-thirds majority vote of each of the donor and implementer groups), the voting thresholds for the selection of the final candidate will be gradually lowered as follows, so that the final candidate will be appointed to the position of Executive Director with the approval of a: <ol type="i"> <li>Qualified Two-Thirds Majority vote: Two-Thirds Majority of the full Board and Simple Majority (i.e., over one-half) in each of the donor and implementer groups;</li> <li>Simple Two-Thirds Majority vote: Two-Thirds Majority by the full Board, without regard to groups, if the final candidate is not selected through the Qualified Two-Thirds Majority vote described in (i) above; or</li> <li>Simple Majority vote: Over 50% of the vote by the full Board, without regard to groups, if the final candidate is not selected through the Simple Two-Thirds Majority vote described in (ii) above.</li> </ol> </li> </ol> </li> </ol>
2017-10-13 B37 GF/B37/EDP05 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Period
<p>1.1 Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,051,987,870 and € 105,315,127.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B37/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches;</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP; and</li> <li>For country disease components specifically noted in Table 1, notes that the final upper-ceiling for such country disease components may be adjusted to reflect a redistribution of funding across country disease components for the applicant, provided that (a) any redistribution of funding is invested in activities validated by the TRP, and (b) the final upper-ceilings for such country disease components will be subject to Board approval.</li> </ol>
2017-10-13 B37 GF/B37/EDP06 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B37/ER04.</li> </ol>
2017-11-17 B37 GF/B37/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>1.1 Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 1,117,868,607 and € 108,755,207, this includes allocation funding as well as US$ 27,873,561 of catalytic investments for matching funds.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B37/EDP07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP;</li> </ol>